A Randomized, Double‐Blind, Placebo‐Controlled Trial of Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis: Results of the Maintenance Period of the TOUCHSTONE Study: 1841. (October 2015) - Hanauer, Stephen B.; Feagan, Brian; Wolf, Douglas C.; D'Haens, Geert; Vermeire, Séverine; Ghosh, Subrata; Smith, Heather; Cravets, Matt; Frohna, Paul; Aranda, Richard; Gujrathi, Sheila; Olson, Allan; et al.